RxDoctor Payments DataLook up a doctor →

Esther Kim, MD

Retina Specialist · Santa Ana, CANPI 1649539404

Payments from drug & device makers

$366,680in general payments, 2019–2025

Across 591 payments — averaging $620.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$111K
  • Apellis Pharmaceuticals, Inc.$90K
  • Astellas Pharma US Inc$87K
  • Genentech USA, Inc.$42K
  • ANI Pharmaceuticals, Inc.$11K
  • Regeneron$8K
  • plus $18K from 18 others

What the payments were for

  • Consulting fees$157,06343%
  • Speaking & faculty fees$165,91045%
  • Travel & lodging$26,4037%
  • Food & beverage$17,3035%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$366,680 in reported general payments places this provider in the 80th percentile of 187 retina specialist providers in California.

See all retina specialist providers in California

Medicare billing

Part B allowed, 2024
$6,202,942
Medicare patients
998
Services billed
69,395

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine37$40,281
XiidraLifitegrast36$33,740
MieboPerfluorohexyloctane/Pf25$18,593
Cyclosporine40$15,036
VevyeCyclosporine20$14,871
SimbrinzaBrinzolamide/Brimonidine Tart34$7,674
TyrvayaVarenicline Tartrate11$6,708
ProlensaBromfenac Sodium19$6,316
Prednisolone Acetate182$5,690
Bromfenac Sodium40$5,451
CombiganBrimonidine Tartrate/Timolol19$4,932
RocklatanNetarsudil Mesylat/Latanoprost12$3,925
Loteprednol Etabonate21$3,296
Ketorolac Tromethamine118$1,803
MoxifloxacinMoxifloxacin Hcl56$1,108

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra, Miebo$290$52,33461 claims
AbbVieRestasis, Combigan$748$45,21356 claims
Harrow Eye, LLCVevye$337$14,87120 claims
AlconSimbrinza$3,156$7,67434 claims
Oyster Point Pharma, Inc.Tyrvaya$87$6,70811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 187 retina specialist providers in California.

Other retina specialist in Santa Ana

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →